Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Non-Current Assets (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Non-Current Assets for 5 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 28.69% year-over-year to $5.7 million, compared with a TTM value of $26.3 million through Dec 2025, down 26.32%, and an annual FY2025 reading of $5.7 million, down 28.69% over the prior year.
  • Non-Current Assets was $5.7 million for Q4 2025 at Aligos Therapeutics, down from $6.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $30.9 million in Q4 2021 and bottomed at $5.7 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $12.0 million, with a median of $11.5 million recorded in 2023.
  • Peak annual rise in Non-Current Assets hit 4.62% in 2022, while the deepest fall reached 57.51% in 2022.
  • Year by year, Non-Current Assets stood at $30.9 million in 2021, then plummeted by 57.51% to $13.1 million in 2022, then decreased by 20.57% to $10.4 million in 2023, then fell by 23.84% to $8.0 million in 2024, then dropped by 28.69% to $5.7 million in 2025.
  • Business Quant data shows Non-Current Assets for ALGS at $5.7 million in Q4 2025, $6.3 million in Q3 2025, and $6.8 million in Q2 2025.